News | December 17, 2023
Dr. Reddy's becomes first Indian pharma company to debut on the DJSI
Dr. Reddy's has been awarded 'Gold Medal' status by EcoVadis
Dr. Reddy's has been awarded 'Gold Medal' status by EcoVadis
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
Vidya will spark conversations around less discussed and important aspects of health, including intimate care and sleep issues
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
Effective, holistic, science-backed targeted solutions for symptomatic treatment
The company has also been named among global sustainability leaders for the 7th year in a row in the Dow Jones Sustainability Index in the Emerging Markets category
The company sees the business reaching $100mn
_256_384.jpg)
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
Dr. Reddy’s included in S&P Global’s Sustainability Yearbook for the 2nd year and Bloomberg Gender-Equality Index for the 5th year in a row
Subscribe To Our Newsletter & Stay Updated
